Page 26 - Preclinical Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

COVID-19 cases continue to escalate worldwide The original announcement by the National Research Council of Canada is available at bit.ly/2JRa4fQ. BOLD-100 is a first-in-class ruthenium-based small molecule drug which selectively inhibits stress-induced upregulation of the chaperone protein GRP78. Currently, the investigational treatment is in a Phase 1b clinical trial in gastrointestinal cancer. In cancer, GRP78 plays a critical role in resistance, survival and proliferation, whereas in viral infections, GRP78 plays a critical role in host recognition, viral entry and viral replication. Prec...

>> there is various implants in the market. this will last several months. it varies from patient to patient. we like to say it lasts typically long enough to get through a lot of psychosocial treatment so that person can have a better chance at long term sobriety by dealing with the underlying causes. again, this is just a tool to help you get through the rough patch. ainsley: how much does it cost. >> some insurance is starting to pay for it that's why we need a lot of help it really does work. it ranges from coast to coast, depending on the treatment provided. they are incident grating this...